Literature DB >> 11063144

Delayed onset of uveitis in TINU syndrome.

R Azar1, C Verove, A Boldron.   

Abstract

We report here the clinical features and outcomes of two patients who presented idiopathic tubulo-interstitial nephritis and uveitis syndrome (TINU syndrome) with ocular disease following the onset of nephropathy. The initial symptoms were renal impairment with asthenia, anorexia and weight loss. An increase in urinary beta2-microglobulin was noticed at the initial checkup in both patients. Renal biopsies showed interstitial cellular infiltration without granulomas or tubular atrophy. No glomerular and vascular alterations were seen and immunofluorescent staining was uniformly negative. Systemic steroid therapy was given and renal function returned to normal within three months. Anterior uveitis occurred in both patients eight months later and responded well to local steroid therapy. Renal involvement in TINU syndrome mostly has a favorable outcome. Despite the possibility of spontaneous regression, systemic steroids may be beneficial in reducing the development of interstitial fibrosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11063144

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  3 in total

1.  A case report of tubulo-interstitial nephritis with uveitis (TINU syndrome) and follow-up for one year.

Authors:  Chadi Alkhalil; Fawad A Tanvir; Abdurahman Ahmed; David Lowenthal
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

2.  Tubulointerstitial nephritis and uveitis syndrome in an elderly woman.

Authors:  Mahmoud Abdelghany; Samer Nasser; George Frem; Curtis Goldblatt
Journal:  Clin Kidney J       Date:  2014-06-09

3.  Tubulointerstitial Nephritis and Uveitis Syndrome in an Elderly Man: Case Report and Literature Review.

Authors:  Wen-Hui Lei; Jun Xin; Xue-Ping Yu; Jie Li; Ming-Feng Mao; Jian-Song Ji; Chui-Fen Wu; Chao-Yong Zhu; Lie Jin
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.